28-Mar-2024
WPRT, FIVN and FATE are among after hour movers
Seeking Alpha News (Mon, 25-Mar 5:15 PM ET)
Lexicon Pharmaceuticals files to sell 57.66M shares for holders
Seeking Alpha News (Mon, 25-Mar 4:35 PM ET)
Globe Newswire (Mon, 25-Mar 9:20 AM ET)
Globe Newswire (Tue, 12-Mar 8:00 AM ET)
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
Globe Newswire (Mon, 11-Mar 7:15 AM ET)
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
Globe Newswire (Mon, 11-Mar 7:05 AM ET)
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
Globe Newswire (Mon, 11-Mar 7:00 AM ET)
Globe Newswire (Mon, 8-Jan 7:00 AM ET)
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.
As of March 28, 2024, LXRX stock price climbed to $2.40 with 6,974,721 million shares trading.
LXRX has a beta of 1.30, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.02 to the broad based SPY ETF.
LXRX has a market cap of $590.97 million. This is considered a Small Cap stock.
Last quarter Lexicon Pharmaceuticals reported $702,000 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-538,000 and exceeded earnings estimates by $.02.
In the last 3 years, LXRX stock traded as high as $6.33 and as low as $.92.
The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, SCHA, IWN.
LXRX has underperformed the market in the last year with a price return of +3.9% while the SPY ETF gained +33.6%. However, in the short term, LXRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +64.4% vs +10.1% return in SPY. But in the last 2 weeks, LXRX shares have been beat by the market, returning -3.2% compared to an SPY return of +1.7%.
LXRX support price is $2.06 and resistance is $2.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX stock will trade within this expected range on the day.